Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy
Pharmacology, Toxicology and Pharmaceutical Science
3
5%
Nursing and Health Professions
3
5%
Biochemistry, Genetics and Molecular Biology
1
2%
Economics, Econometrics and Finance
1
2%
Other
2
3%
Unknown
31
52%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 February 2020.
All research outputs
#11,416,998
of 32,375,021 outputs
Outputs from Clinical Colorectal Cancer
#278
of 640 outputs
Outputs of similar age
#150,201
of 362,117 outputs
Outputs of similar age from Clinical Colorectal Cancer
#8
of 21 outputs
Altmetric has tracked 32,375,021 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 640 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 362,117 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
